Three-year survival update confirms efficacy of pembrolizumab in non-small cell lung cancer - Healio

Three-year survival update confirms efficacy of pembrolizumab in non-small cell lung cancer  Healio

BARCELONA — First-line pembrolizumab monotherapy conferred a durable long-term OS benefit compared with chemotherapy for patients with metastatic, ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...